Complera contains a mixture of emtricitabine, rilpivirine, and tenofovir. Emtricitabine, rilpivirine, and tenofovir area unitantiviral medication that stop HIV (human immunological disorder virus) cells from multiplying within the body. HIV causes noninheritable immunological disorder syndrome (AIDS).

Complera is employed to treat HIV in adults World Health Organization have not taken HIV medicines before.

Complera isn’t a cure for HIV or AIDS.

Complera shouldn’t be taken in conjunction with alternative antiviral medications to treat HIV or AIDS.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • Complera
  • Get emergency medical help if you have signs of an allergic reaction to Complera: hives, blistering skin rash with fever; mouth sores, eye redness, difficulty breathing; swelling of your face, lips, tongue, or throat.

    Some people develop lactic acidosis while taking Complera. Early symptoms may get worse over time and this condition can be fatal. Get emergency medical help if you have even mild symptoms such as: muscle pain or weakness, numb or cold feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, fast or uneven heart rate, dizziness, or feeling very weak or tired.

    Call your doctor at once if you have:

    confusion, severe depression, unusual thoughts or behavior, suicidal thoughts or actions;
    increased thirst and urination, loss of appetite, weakness, constipation;
    kidney problems - little or no urinating, painful or difficult urination, swelling in your feet or ankles, feeling tired or short of breath;
    liver problems - nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
    signs of inflammation in your body - swollen glands, flu symptoms, easy bruising or bleeding, severe tingling or numbness, muscle weakness, upper stomach pain, jaundice (yellowing of the skin or eyes), chest pain, new or worsening cough with fever, trouble breathing.
    Complera may increase your risk of certain infections or autoimmune disorders by changing the way your immune system works. Symptoms may occur weeks or months after you start treatment with Complera. Tell your doctor if you have:

    signs of a new infection - fever, night sweats, swollen glands, diarrhea, weight loss;
    chest pain (especially when you breathe), dry cough, wheezing;
    cold sores, sores on your genital or anal area;
    feeling anxious or irritable, weakness or prickly feeling, problems with balance or eye movement;
    trouble speaking or swallowing, severe lower back pain, loss of bladder or bowel control; or
    swelling in your neck or throat (enlarged thyroid), menstrual changes, impotence, loss of interest in sex.
    Common Complera side effects may include:

    headache, dizziness;
    depressed mood, tiredness;
    sleep problems (insomnia), strange dreams;
    nausea, diarrhea; or
    changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).
  • 1 tablet orally once a day Comments: -Efficacy was established in virologically-suppressed (HIV-1 RNA less than 50 copies/mL) patients on stable ritonavir-boosted protease inhibitor-containing regimen. -Replacement of current regimen with this drug may be considered if: patients have no history of virologic failure; patients have been stably suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months before switching therapy; patients are currently on first or second antiretroviral regimen before switching therapy; patients have no history of resistance to any of the 3 components. -After replacing therapy, additional monitoring of HIV-1 RNA and regimen tolerability recommended to assess potential virologic failure or rebound. Use: As a complete regimen for the treatment of HIV-1 infection in antiretroviral therapy-naive patients with HIV-1 RNA 100,000 copies/mL or less at the start of therapy, and in certain virologically-suppressed (HIV-1 RNA less than 50 copies/mL) patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen